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Continuous synthesis of artemisinin-derived
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D. Tyler McQuade,a Andreas Seidel-Morgensternbc and Peter H. Seeberger*ad
Described is a continuous, divergent synthesis system which is coupled
to continuous purification and is capable of producing four anti-malarial
APIs. The system is comprised of three linked reaction modules for
photooxidation/cyclization, reduction, and derivatization. A fourth
module couples the crude reaction streamwith continuous purification
to yield pure API.
As the global demand for medicines has increased, efforts to
implement continuous Active-Pharmaceutical Ingredient (API)
production have intensified.1 Continuous processes hold many
potential benefits including increased safety and product quality,
as well as lower environmental impact.2 While proof-of-concept
continuous API syntheses3,4 focused on linear transformations, we
describe the combination of a divergent, multi-step continuous
synthesis with continuous in-line purification to prepare several
artemisinin-derived APIs that are key components in Artemisinin
Combination Therapies (ACT), the World Health Organization’s
(WHO) recommended first-line treatment for malaria.
Today, the key active pharmaceutical ingredients of all ACT
anti-malarials are produced in one or two chemical steps from
artemisinin (3) (Fig. 1). The majority of artemisinin (B200 tons
per year) is extracted from the plant Artemisia annua and prices
fluctuate with harvest yields.5 The plant waste material dihydro-
artemisinic acid (DHAA) 2 has also been used to synthesise
artemisinin via continuous flow photochemistry with subsequent
acid-induced rearrangement, resulting in a fast (residence time
less than 12 minutes) and efficient (69% yield) transformation.6,7
ACT medications rely not only on the procurement of
artemisinin, but also its conversion to the corresponding APIs
(4–7). To achieve a completely continuous synthesis and purification
of the three main anti-malarial APIs, we built upon the previously
described continuous synthesis of artemisinin 3 from DHAA 2
(Fig. 3, module 1).6 While lithium triethylborohydride (Super-
hydrides) effects the reduction of pure artemisinin 3 to DHA 4
in a continuous flow chemistry setting,8 this reagent is an order
of magnitude more expensive than the NaBH4 used in traditional
batch syntheses. Super-hydrides is even more expensive than
artemisinin, making it unsuitable for the production of a price-
sensitive API. Consequently, a continuous process using inexpensive
NaBH4 had to be developed.
9
Several challenges had to be overcome, including the insolubility
of NaBH4 in the toluene–TFA solvent mixtures exiting module 1.
While NaBH4 suspensions have been used in batch to prepare DHA,
the use of slurries in flow remains a major challenge,10 particularly
Fig. 1 Overall production scheme of anti-malaria APIs from artemisinin
obtained by traditional extraction from Artemisia annua and genetically
modified yeast combined with chemical modification. Dihydroartemisinin
(4, combined with piperaquine in Eurartesim, Artekin and Duo-Cotecxin),
b-artemether (5, combined with lumefantrine in Coartem), b-arteether
(6, Artemotil), and a-artesunate (7, combined with amodiaquine in Coarsucam
and ASAQ-Winthrop).
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when envisioning prolonged production runs. A NaBH4-containing
packed-bed column would be an attractive means of reducing 3 to 4.
While packed-beds containing NaBH4/Celite
smixtures (1 :1 (w/w))11
successfully reduced artemisinin from the outflow of module 1
to DHA, columns packed in this way proved unstable (see ESI†).
Different column additives to both accelerate the reduction and
stabilise the column were screened (Fig. 2). Lithium chloride
(LiCl) accelerates NaBH4 reductions via the in situ formation of
LiBH4,
12 but clogging remained a problem. Buffering the trifluoro-
acetic acid (TFA) contained in the reaction stream by the addition
of lithium carbonate (Li2CO3) also did not remedy the clogging
problems. However, upon combining the two additives and mixing
NaBH4, Celite
s, Li2CO3, and LiCl (1 : 1 : 1 : 0.76 (w/w)) as packed-
bed materials and using an alcohol co-solvent such as ethanol,12
complete and clean reduction of crude artemisinin was achieved
(Fig. 2, red line). By combining modules 1 and 2, the first API (4) is
produced from DHAA 2, with module 2 representing a general
solution to achieve efficient reductions of carbonyl compounds in
continuous flow, with a reduction capacity which is stoichiometric
with respect to NaBH4.
13
The mixed methyl acetal 5, API of the drug Coartem, is
accessed by combining artemisinin reduction and methyl ether
formation (modules 2 and 3, Fig. 3). Previous attempts at
developing a combined continuous process were unsuccessful
due to sensitivity following NaBH4 reduction.
14 As such, the
effects of both hydride source (1 M LiEt3BH or reduction
column) and workup conditions on the resulting epimeric ratio
of b : a artemether were examined in batch following treatment
with Feed BAM (1.8 M HCl in 2 : 1 v/v methanol/trimethyl
orthoformate). The ratio was determined by 1H NMR of the
crude reaction mixture following basic workup of the second step,
comparing the doublets at 4.65 ppm (b-artemether 5, J = 4 Hz) and
4.32 ppm (a-artemether, J = 8 Hz).15
As expected, the telescoping of the reduction and mixed acetal
formation without any intermediate workup resulted in a poor
mixture of artemether epimers for both hydride sources (Table 1,
entries 1 and 4).14 It appears the intermediate alkoxyborane species
that is formed upon reduction using LiEt3BH is stronger than that
emanating from Na/LiBH4, thus requiring an ethanolamine wash to
break it down and give acceptable epimeric ratios (entries 2 and 3).
However, upon exiting the reduction column, a simple aqueous
wash (entry 5) was sufficient to obtain epimeric ratios equal to those
resulting from pure dihydroartemisinin.14
In flow, the reaction stream exiting module 2 (pHB 10) was
continuously degassed16 and extracted17 with water before the
organic stream was combined with Feed BAM via a T-mixer.
Complete etherification occurred within a 25 minute residence
time at 25 1C, providing artemether 5 as a 81 : 19 ratio of b : a
epimers, similar to that obtained via traditional batch synthesis.14
b-Artemether 5 was obtained in 25% overall yield from DHAA 2
following basic workup and isolation. In a similar manner, artemotil
6 was obtained as a 5 :1 mixture of epimers (b :a) in 22% yield from
2when Feed BAE consisted of a 1.8MHCl solution in ethanol/triethyl
orthoformate (2 :1 v/v).
Artesunate 7, the active ingredient in Coarsucam, was con-
tinuously prepared from DHAA using a succinic anhydride
solution (1.6 M containing one equiv. triethylamine in dichloro-
methane) in Feed BAS at a 25 minute residence time at 25 1C.
Exclusively the desired a-epimer was formed, to yield 7 in 28%
from DHAA 2. The crude solution of this derivative was used to
demonstrate continuous purification (vide infra).
The entire three module continuous flow process to convert
2 to the APIs 5–7 requires a reaction time of 46 minutes
(3.4 mmol per hour through the laboratory-scale system).
Importantly, not only can 5, 6, or 7 be synthesised simply by
exchanging the solution in Feed B and the acid/base quench
(Fig. 3), any further artemisinin C10 derivatives that are under
investigation as future anti-malarial APIs18 can be prepared by
using this modular synthesis system.
Fig. 2 System pressure observed during reduction of crude artemisinin 3
as a function of cosolvent and solid additives in the Celites/NaBH4 column.
Fig. 3 Four module system for the continuous synthesis and purification
of artemisinin APIs (in red text). TFA: trifluoroacetic acid, EtOH: ethanol.
Table 1 The effect of hydride source and intermediate wash on the
epimeric ratio of artemether following treatment with Feed BAM in batch
Entry Hydride source Intermediate wash b :a
1 Superhydrides (LiHEt3) None 50 : 50
2 Superhydrides (LiHEt3) H2O 50 : 50
3 Superhydrides (LiHEt3) H2O/ethanolamine (3/1, v/v) 80 : 20
4 NaBH4 Column None 75 : 25
5 NaBH4 Column H2O 81 : 19
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With the chemical steps defined, continuous monitoring
and purification were introduced. FlowIR has been shown to be
efficient to observe continuous systems in real time19 and was
utilized to monitor the system after each reaction module. In
module 1, the plant waste material DHAA 2 is converted to
artemisinin 3. When the lamp was turned off to simulate a
‘‘lamp failure’’, the result is observed approximately 11 minutes
later when product 3 (1033 cm1) was no longer observed in the
IR trace (Fig. 4). Similarly, the outputs from modules 2 and 3
were also successfully monitored (see ESI†), allowing for facile
quality control at each stage of production.
The continuous synthesis of drug substances is ideally
complemented by continuous purification to yield pure APIs
that meet the standards set by regulatory bodies such as the FDA20
or WHO.21 To demonstrate the power of the fully continuous
synthesis/purification regime, a continuous three-stage purification
method (filtration/multi-column chromatography/crystallisation)
was developed for a-artesunate 7. The first stage dilutes the stream
exiting module 3 with n-hexane, which decreases the solvent
strength and precipitates polar byproducts. The recovery yield
of 7 after dilution and filtration of the reaction mixture is 65%.
Following filtration, the artesunate-containing stream can enter a
separator consisting of five identical chromatography columns
participating in the following steps: loading, elution, rinsing, and
equilibration (see ESI†). This multi-column arrangement, together
with the periodic switching between two filters, permits a permanent
feed supply. The artesunate fraction can be subsequently fed directly
into a continuous crystalliser to remove the remaining impurities
(Fig. 5). With 73% of 7 recovered from the crystalliser, the overall
recovery yield of a-artesunate from the crude exit stream ofmodule 3
is 48% with an HPLC purity of greater than 99.5%, exceeding the
requirements set by the WHO.21
This continuous,modular approach for the divergent synthesis of
small molecules has attractive scientific and conceptual implica-
tions. Batch processes are significantly more labour-intensive, as
they require solvent removal and purification of the intermediates
following each step. The use of potentially dangerous reagents, such
as oxygen or sodium borohydride, becomes possible in flow and
allows for new reaction pathways,22 and the ability to combine/
interchange different reaction modules allows for the production of
a variety of APIs. The synthesis of the four anti-malarial APIs
described here illustrates this principle and with this first example
of a divergent, multi-step continuous synthesis and purification
process, many routes to APIs of generic and patented drugs can
be envisioned.
We gratefully acknowledge financial support from the Max-
Planck Society. We thank Mettler-Toledo for the use of the FlowIR
instrument.
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